U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H22N2O5
Molecular Weight 394.4205
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VARESPLADIB METHYL

SMILES

CCC1=C(C(=O)C(N)=O)C2=C(C=CC=C2OCC(=O)OC)N1CC3=CC=CC=C3

InChI

InChIKey=VJYDOJXJUCJUHL-UHFFFAOYSA-N
InChI=1S/C22H22N2O5/c1-3-15-20(21(26)22(23)27)19-16(24(15)12-14-8-5-4-6-9-14)10-7-11-17(19)29-13-18(25)28-2/h4-11H,3,12-13H2,1-2H3,(H2,23,27)

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/10027849

Varespladib (LY315920; A-001) is a potent and selective inhibitor of IIa, V, and X isoforms of human non-pancreatic secretory phospholipase A2 with nM IC50. The molecule acts as an anti-inflammatory agent by disrupting the first step of the arachidonic acid pathway of inflammation. Varespladib methyl is being developed by Anthera Pharmaceuticals Inc for the potential treatment of coronary artery disease, acute coronary syndrome and inflammation. Varespladib methyl is a prodrug that is rapidly metabolized to varespladib, and both compounds are able to potently inhibit the enzymes of the human secretory phospholipase groups. Phase II clinical trials of varespladib methyl in patients with coronary artery disease, rheumatoid arthritis, asthma and ulcerative colitis revealed that the drug was well tolerated. Varespladib methyl did not demonstrate a good efficacy profile in patients with rheumatoid arthritis, asthma and ulcerative colitis; whereas in patients with coronary artery disease, varespladib methyl consistently reduced LDL-cholesterol levels, (elevated LDL-cholesterol levels are a marker of increased cardiovascular risk). Varespladib methyl could represent a novel therapy for the treatment of cardiovascular disease, although the efficacy, safety profile and advantages of this drug compared with existing therapeutic options would need to be established in upcoming phase III trials.

Approval Year

Doses

Doses

DosePopulationAdverse events​
500 mg 1 times / day multiple, oral
Studied dose
Dose: 500 mg, 1 times / day
Route: oral
Route: multiple
Dose: 500 mg, 1 times / day
Sources:
unhealthy
n = 2572
Health Status: unhealthy
Condition: Acute Coronary Syndrome
Sex: M+F
Food Status: UNKNOWN
Population Size: 2572
Sources:
Disc. AE: aspartate transaminase elevations, aspartate transaminase elevations...
AEs leading to
discontinuation/dose reduction:
aspartate transaminase elevations (1.5%)
aspartate transaminase elevations (1.5%)
Sources:
AEs

AEs

AESignificanceDosePopulation
aspartate transaminase elevations 1.5%
Disc. AE
500 mg 1 times / day multiple, oral
Studied dose
Dose: 500 mg, 1 times / day
Route: oral
Route: multiple
Dose: 500 mg, 1 times / day
Sources:
unhealthy
n = 2572
Health Status: unhealthy
Condition: Acute Coronary Syndrome
Sex: M+F
Food Status: UNKNOWN
Population Size: 2572
Sources:
aspartate transaminase elevations 1.5%
Disc. AE
500 mg 1 times / day multiple, oral
Studied dose
Dose: 500 mg, 1 times / day
Route: oral
Route: multiple
Dose: 500 mg, 1 times / day
Sources:
unhealthy
n = 2572
Health Status: unhealthy
Condition: Acute Coronary Syndrome
Sex: M+F
Food Status: UNKNOWN
Population Size: 2572
Sources:
PubMed

PubMed

TitleDatePubMed
An update on inhibitors of human 14 kDa Type II s-PLA2 in development.
2001 Feb
Regioselective synthesis of 4- and 7-alkoxyindoles from 2,3-dihalophenols: application to the preparation of indole inhibitors of phospholipase A2.
2007 Jul 6
Patents

Sample Use Guides

Unknown
Route of Administration: Oral
LY315920 (VARESPLADIB) (10 μM) significantly inhibits all-trans-retinoic acid (RA) -induced membrane-associated mucin MUC16 expression by 100% at 24 hours and 99% at 48 hours.
Name Type Language
VARESPLADIB METHYL
USAN  
USAN  
Official Name English
ACETIC ACID, ((3-(AMINOOXOACETYL)-2-ETHYL-1-(PHENYLMETHYL)-1H-INDOL-4-YL)OXY)-, METHYL ESTER
Common Name English
VARESPLADIB METHYL ESTER [MI]
Common Name English
METHYL ((3-(AMINOOXOACETYL)-2-ETHYL-1-(PHENYLMETHYL)-1H-INDOL-4-YL)OXY)ACETATE
Systematic Name English
S-3013
Code English
LY-333013
Code English
LY333013
Code English
VARESPLADIB METHYL [USAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C471
Created by admin on Fri Dec 15 15:33:37 GMT 2023 , Edited by admin on Fri Dec 15 15:33:37 GMT 2023
NCI_THESAURUS C257
Created by admin on Fri Dec 15 15:33:37 GMT 2023 , Edited by admin on Fri Dec 15 15:33:37 GMT 2023
Code System Code Type Description
PUBCHEM
9886917
Created by admin on Fri Dec 15 15:33:37 GMT 2023 , Edited by admin on Fri Dec 15 15:33:37 GMT 2023
PRIMARY
ChEMBL
CHEMBL2105659
Created by admin on Fri Dec 15 15:33:37 GMT 2023 , Edited by admin on Fri Dec 15 15:33:37 GMT 2023
PRIMARY
NCI_THESAURUS
C152833
Created by admin on Fri Dec 15 15:33:37 GMT 2023 , Edited by admin on Fri Dec 15 15:33:37 GMT 2023
PRIMARY
FDA UNII
0NB98NBX3D
Created by admin on Fri Dec 15 15:33:37 GMT 2023 , Edited by admin on Fri Dec 15 15:33:37 GMT 2023
PRIMARY
WIKIPEDIA
VARESPLADIB METHYL
Created by admin on Fri Dec 15 15:33:37 GMT 2023 , Edited by admin on Fri Dec 15 15:33:37 GMT 2023
PRIMARY
EPA CompTox
DTXSID40938196
Created by admin on Fri Dec 15 15:33:37 GMT 2023 , Edited by admin on Fri Dec 15 15:33:37 GMT 2023
PRIMARY
USAN
UU-54
Created by admin on Fri Dec 15 15:33:37 GMT 2023 , Edited by admin on Fri Dec 15 15:33:37 GMT 2023
PRIMARY
MERCK INDEX
m11396
Created by admin on Fri Dec 15 15:33:37 GMT 2023 , Edited by admin on Fri Dec 15 15:33:37 GMT 2023
PRIMARY Merck Index
SMS_ID
300000044643
Created by admin on Fri Dec 15 15:33:37 GMT 2023 , Edited by admin on Fri Dec 15 15:33:37 GMT 2023
PRIMARY
DRUG BANK
DB05737
Created by admin on Fri Dec 15 15:33:37 GMT 2023 , Edited by admin on Fri Dec 15 15:33:37 GMT 2023
PRIMARY
CAS
172733-08-3
Created by admin on Fri Dec 15 15:33:37 GMT 2023 , Edited by admin on Fri Dec 15 15:33:37 GMT 2023
PRIMARY
MESH
C545088
Created by admin on Fri Dec 15 15:33:37 GMT 2023 , Edited by admin on Fri Dec 15 15:33:37 GMT 2023
PRIMARY